Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 24, 2022, BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") held its 2022 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 184,898,129 shares of common stock were entitled to vote as of March 28, 2022, the record date for the Annual Meeting. There were 157,248,760 shares of common stock present in person or represented by proxy at the Annual Meeting at which the stockholders were asked to vote on three proposals, each of which is described in more detail in BioMarin's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 12, 2022 (the "Proxy Statement"). Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal.

Proposal No. 1: Election of Directors



                                                             Broker
Directors Elected                Vote For      Withheld    Non-Votes
Mark J. Alles                   134,357,621   12,349,973   10,541,166
Elizabeth McKee Anderson        138,852,305   7,855,289    10,541,166
Jean-Jacques Bienaimé           133,104,668   13,602,926   10,541,166
Willard Dere, M.D.              141,281,714   5,425,880    10,541,166
Elaine J. Heron, Ph.D.          129,036,966   17,670,628   10,541,166
Maykin Ho                       146,007,145    700,449     10,541,166
Robert J. Hombach               141,119,244   5,588,350    10,541,166
V. Bryan Lawlis, Ph.D.          140,266,110   6,441,484    10,541,166
Richard A. Meier                140,377,231   6,330,363    10,541,166
David E.I. Pyott, M.D. (Hon.)   139,737,870   6,969,724    10,541,166
Dennis J. Slamon, M.D., Ph.D.   143,191,445   3,516,149    10,541,166

Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director's death, resignation or removal.

Proposal No. 2: Ratification of the Selection of Independent Registered Public Accounting Firm

The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2022, as set forth in the Proxy Statement, received the following votes:



    For        Against    Abstain
153,373,736   3,776,965   98,059

Based on the votes set forth above, BioMarin's stockholders ratified the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2022.

Proposal No. 3: Advisory Vote on the Compensation of Named Executive Officers

The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the following votes:



                                        Broker
   For        Against      Abstain    Non-Votes
79,494,727   64,157,192   3,055,675   10,541,166

Based on the votes set forth above, BioMarin's stockholders approved, on an advisory basis, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses